ReviewCancer epidemiology2026
Cervical cancer burden and elimination readiness in the US-affiliated Pacific Islands: A structured narrative review.
Review in Cancer epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe US-Affiliated Pacific Islands (USAPI) experience a high burden of cervical cancer, but progress toward achieving cervical cancer elimination targets is difficult to assess due to limited and fragmented data on HPV vaccination, cervical cancer screening and cancer treatment access. This narrative review aims to synthesise evidence of disease burden, risk factors, and interventions to inform region-specific strategies.
methodsWe conducted a structured narrative review of published literature (MEDLINE, Embase, Global Health), cancer registry data, surveillance reports, and health system registries for six USAPI jurisdictions from 1990 to 2025. We collated information on HPV, cervical precancers and cancers, and related risk factors. Information on HPV vaccination, cervical cancer screening, and treatment, obtained from jurisdictional health system registries and reports, was used to assess the region's trajectory towards the elimination targets.
findingsCervical cancer incidence among women aged ≥ 20 years during 2007-2022 in the USAPI (age-standardized rate:17.2/100,000;95%CI:15.6-18.8) exceeded that of the US (10.8/100,000;95%CI:10.7-10.8), with large variation across jurisdictions, from 8.4/100,000 in American Samoa to 68.9/100,000 in Republic of the Marshall Islands (RMI). Approximately 75% of cases were diagnosed at Stage III + . HPV vaccination was introduced between 2007-2016, with coverages ranging from 44.2% in Federated States of Micronesia (FSM) to 92.7% in Commonwealth of the Northern Mariana Islands (CNMI). Four jurisdictions have implemented cytology-based screening, whereas RMI/FSM primarily rely on visual inspection with acetic acid. Screening coverage varies from 14.2% (CNMI, 2019) to 67.8% (Guam, 2020). Cancer treatment capacity is limited, with most jurisdictions lacking radiotherapy and relying on off-island referrals for advanced cases.
interpretationUSAPI cervical cancer burden is substantially higher than the US, compounded by late-stage diagnoses and limited treatment capacity. Although vaccination coverage has improved, major gaps remain in screening, follow-up, and access to care. Strengthening health systems through scalable, resource-appropriate strategies will accelerate progress toward elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.